Cabozantinib
Renal Cell Carcinoma
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
SWOG Cancer Research Network
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07383441CT.gov Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | — | Recruiting | — | — | — |
NCT07620574CT.gov Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | — | Not Yet Recruiting | — | — | — |
NCT07293351CT.gov A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | — | Recruiting | — | — | — |
NCT07405164CT.gov Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | — | Recruiting | — | — | — |
NCT07077161CT.gov Cabozantinib Dose Skipping as an Alternative to Dose Reductions | — | Recruiting | — | — | — |
NCT07227402CT.gov A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) | — | Recruiting | — | — | — |
NCT07028125CT.gov Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma | — | Recruiting | — | — | — |
NCT06934057CT.gov Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT06835972CT.gov A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | — | Recruiting | — | — | — |
NCT06726421CT.gov Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) | — | Recruiting | — | — | — |
Show 51 more trialsShow fewer
NCT06548867CT.gov Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib | — | Recruiting | — | — | — |
NCT05931393CT.gov Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) | — | Recruiting | — | — | — |
NCT06132945CT.gov A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain | — | Active Not Recruiting | — | — | — |
NCT06026410CT.gov KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05127824CT.gov Autologous Dendritic Cell Vaccine in Kidney Cancer | — | Recruiting | — | — | — |
NCT05411081CT.gov Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial | — | Active Not Recruiting | — | — | — |
NCT05188118CT.gov Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT05327686CT.gov Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | — | Recruiting | — | — | — |
NCT05361720CT.gov Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | — | Recruiting | — | — | — |
NCT05048212CT.gov A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | — | Recruiting | — | — | — |
NCT05092373CT.gov Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | — | Recruiting | — | — | — |
NCT05012371CT.gov Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | — | Active Not Recruiting | — | — | — |
NCT05263050CT.gov Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | — | Recruiting | — | — | — |
NCT05122546CT.gov CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT04804813CT.gov Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma | — | Completed | — | — | — |
NCT04586231CT.gov A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | — | Active Not Recruiting | — | — | — |
NCT04637204CT.gov Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England | — | Completed | — | — | — |
NCT04413123CT.gov Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | — | Active Not Recruiting | — | — | — |
NCT04540705CT.gov A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread | — | Completed | — | — | — |
NCT04338269CT.gov A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment | — | Terminated | — | — | — |
NCT04322955CT.gov CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | — | Active Not Recruiting | — | — | — |
NCT04353765CT.gov Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors | — | Completed | — | — | — |
NCT03945773CT.gov Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors | — | Completed | — | — | — |
NCT03967522CT.gov Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases | — | Completed | — | — | — |
NCT04510688CT.gov Spanish Real-World Evidence Cabozantinib | — | Completed | — | — | — |
NCT04022343CT.gov Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT03937219CT.gov Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03793166CT.gov Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | — | Active Not Recruiting | — | — | — |
NCT03798626CT.gov Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | — | Completed | — | — | — |
NCT03866382CT.gov Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | — | Recruiting | — | — | — |
NCT03685448CT.gov ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) | — | Completed | — | — | — |
NCT04416646CT.gov Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma | — | Completed | — | — | — |
NCT03729245CT.gov A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | — | Terminated | — | — | — |
NCT06377722CT.gov Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer | — | Terminated | — | — | — |
NCT03634540CT.gov A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | — | Active Not Recruiting | — | — | — |
NCT03635892CT.gov A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03200587CT.gov Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) | — | Completed | — | — | — |
NCT03541902CT.gov Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03428217CT.gov CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma | — | Completed | — | — | — |
NCT03339219CT.gov A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma | — | Completed | — | — | — |
NCT03149822CT.gov Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | — | Completed | — | — | — |
NCT03170960CT.gov Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03141177CT.gov A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT02867592CT.gov Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | — | Active Not Recruiting | — | — | — |
NCT02761057CT.gov Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | — | Completed | — | — | — |
NCT02496208CT.gov Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | — | Active Not Recruiting | — | — | — |
NCT02293980CT.gov A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | — | Active Not Recruiting | — | — | — |
NCT02071862CT.gov Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | — | Completed | — | — | — |
NCT01835158CT.gov Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT01865747CT.gov A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | — | Completed | — | — | — |
NCT01100619CT.gov A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cabozantinib (this asset) | SWOG Cancer Research Network | Approved | BB · 64 |
| Sorafenib | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P4 | BBB |
| Pazopanib | Imbioray (Hangzhou) Biomedicine Co., Ltd. | P4 | BBB |
| Belzutifan | Vall d'Hebron Institute of Oncology | P3 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Interferon-Alfa-2A | Central European Society for Anticancer Drug Research | P3 | BB |
| Everolimus | Merck Sharp & Dohme LLC | P4 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P4 | BB |
+42 more in the Renal Cell Carcinoma cohort
Other indications for Cabozantinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BB · 70 |
| Castration-Resistant Prostate Carcinoma | — | P3 | BB · 70 |
| Kidney Cancer | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Cabozantinib in Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cabozantinib-renal-cell-carcinoma-48450
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →